2023/24 will be somewhat gloomy
20/11/23 -"We have done a first round of data integration and adjustments to our figures as the annual report will be released in a few days. 2022/23 was helped by the better operating performance in Imaging ..."
Pages
68
Language
English
Published on
20/11/23
You may also be interested by these reports :
10/07/26
Following Thermo Fisher’s unsuccessful bid in 2020, Qiagen gradually restructured its business, focusing on non-COVID growth avenues. However, in ...
10/07/26
Non Pharma Health stocks have long been suffering. The sector has lost 39% ytd, not helped by EssilorLuxottica’s -35% correction. EL’s connected ...
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...